NO20091191L - Fremgangsmater for behandling av kreft, innbefattende administrering av et vitamin D preparat og et ytterligere terapeutisk middel, og sammensetninger som inneholder de samme - Google Patents

Fremgangsmater for behandling av kreft, innbefattende administrering av et vitamin D preparat og et ytterligere terapeutisk middel, og sammensetninger som inneholder de samme

Info

Publication number
NO20091191L
NO20091191L NO20091191A NO20091191A NO20091191L NO 20091191 L NO20091191 L NO 20091191L NO 20091191 A NO20091191 A NO 20091191A NO 20091191 A NO20091191 A NO 20091191A NO 20091191 L NO20091191 L NO 20091191L
Authority
NO
Norway
Prior art keywords
vitamin
cancer
additional therapeutic
therapeutic agent
methods
Prior art date
Application number
NO20091191A
Other languages
English (en)
Inventor
Alan H Auerbach
Arie S Belldegrun
Original Assignee
Cougar Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cougar Biotechnology Inc filed Critical Cougar Biotechnology Inc
Publication of NO20091191L publication Critical patent/NO20091191L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Det beskrives metoder for behandling av cancer omfattende administrering av en vitamin D forbindelse i kombinasjon med minst et ytterligere terapeutisk middel som et anti-cancermiddel eller et steroid. Videre beskrives preparater omfattende vitamin D forbindelser og minst et ytterligere terapeutisk middel som et anti-cancermiddel eller et steroid, f eks. kortikosteroid eller mer spesifikt et glukokortikoid.
NO20091191A 2006-08-25 2009-03-20 Fremgangsmater for behandling av kreft, innbefattende administrering av et vitamin D preparat og et ytterligere terapeutisk middel, og sammensetninger som inneholder de samme NO20091191L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93492406P 2006-08-25 2006-08-25
PCT/US2007/018770 WO2008024485A2 (en) 2006-08-25 2007-08-23 Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent

Publications (1)

Publication Number Publication Date
NO20091191L true NO20091191L (no) 2009-03-23

Family

ID=39107444

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091191A NO20091191L (no) 2006-08-25 2009-03-20 Fremgangsmater for behandling av kreft, innbefattende administrering av et vitamin D preparat og et ytterligere terapeutisk middel, og sammensetninger som inneholder de samme

Country Status (9)

Country Link
EP (2) EP2425874A3 (no)
JP (1) JP2010501576A (no)
KR (1) KR20090060306A (no)
CN (1) CN101528309A (no)
AU (1) AU2007287099A1 (no)
CA (2) CA2838089A1 (no)
IL (1) IL197212A0 (no)
NO (1) NO20091191L (no)
WO (1) WO2008024485A2 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5932339B2 (ja) * 2009-01-27 2016-06-08 バーグ エルエルシー 化学療法に付随する副作用を軽減するためのビタミンｄ３およびその類似体
AU2010264698C1 (en) 2009-06-26 2013-05-16 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP 17
JP2012532925A (ja) * 2009-07-16 2012-12-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 癌の処置のための化合物および方法
WO2012035078A1 (en) 2010-09-16 2012-03-22 Novartis Ag 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
US20120116381A1 (en) 2010-11-05 2012-05-10 Houser Kevin L Surgical instrument with charging station and wireless communication
EA023064B1 (ru) 2011-04-28 2016-04-29 Новартис Аг ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
US9801844B2 (en) * 2012-05-24 2017-10-31 The Research Foundation Of The City University Of New York Methods and compositions for the treatment of cancer
CN104661658A (zh) 2012-09-26 2015-05-27 阿拉贡药品公司 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
CA2909941A1 (en) 2013-04-24 2014-10-30 Salk Institute For Biological Studies Vitamin d receptor/smad genomic circuit gates fibrotic response
BR112015030518A2 (pt) 2013-06-05 2017-08-29 Salk Inst For Biological Studi Composição farmacêutica, uso de um ou mais agonistas do receptor da vitamina d (vdr), e, método para a redução da atividade biológica do ligante 12 do motivo c-x-c (cxcl12)
WO2019023149A1 (en) 2017-07-24 2019-01-31 Salk Institute For Biological Studies USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES
CN111479560A (zh) 2017-10-16 2020-07-31 阿拉贡药品公司 用于治疗非转移性去势难治性前列腺癌的抗雄激素

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120722A (en) 1984-02-08 1992-06-09 Hoffmann-La Roche Inc. Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating leukemia
US4857518A (en) 1984-10-04 1989-08-15 Wisconsin Alumni Research Foundation Hydroxylated 24-homo-vitamin D derivatives and methods for preparing same
US4717721A (en) 1985-05-30 1988-01-05 Howard W. Bremer Sidechain homo-vitamin D compounds with preferential anti-cancer activity
KR940010767B1 (ko) 1985-08-02 1994-11-11 레오 파마슈티칼스 프로덕츠 리미티드 에이/에스(레벤스 케미스케 파브리크 프로덕션 사크티에셀스카브) 신규 비타민 d 동족체
US5145846A (en) 1988-01-20 1992-09-08 Hoffmann-La Roche Inc. Vitamin D3 analogs
US4851401A (en) 1988-07-14 1989-07-25 Wisconsin Alumni Research Foundation Novel cyclopentano-vitamin D analogs
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
GB8915770D0 (en) 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
DE4101953A1 (de) 1991-01-19 1992-07-23 Schering Ag 23-oxa-derivate in der vitamin-d-reihe, verfahren zu ihrer herstellung diese derivate enthaltende pharmazeutische praeparate sowie deren verwendung als arzneimittel
DE4141746A1 (de) 1991-12-13 1993-06-17 Schering Ag 20-methyl-substituierte vitamin d-derivate
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5547947A (en) 1993-03-11 1996-08-20 Hoffmann-La Roche Inc. Methods of treatment
GB9622590D0 (en) 1996-10-30 1997-01-08 Leo Pharm Prod Ltd Chemical compounds
JP2002509888A (ja) 1998-03-27 2002-04-02 オレゴン ヘルス サイエンシーズ ユニバーシティー 腫瘍および他の過増殖性疾患の治療におけるビタミンｄおよびその類似体
DK1276482T3 (da) * 2000-03-02 2008-05-26 Univ Pittsburgh Kombinationskemoterapi
US7094775B2 (en) * 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents

Also Published As

Publication number Publication date
KR20090060306A (ko) 2009-06-11
AU2007287099A1 (en) 2008-02-28
EP2063963A2 (en) 2009-06-03
CA2838089A1 (en) 2008-02-28
WO2008024485A2 (en) 2008-02-28
EP2425874A3 (en) 2013-05-15
EP2425874A2 (en) 2012-03-07
IL197212A0 (en) 2009-12-24
JP2010501576A (ja) 2010-01-21
CA2661546A1 (en) 2008-02-28
WO2008024485A3 (en) 2009-03-05
CN101528309A (zh) 2009-09-09

Similar Documents

Publication Publication Date Title
NO20091191L (no) Fremgangsmater for behandling av kreft, innbefattende administrering av et vitamin D preparat og et ytterligere terapeutisk middel, og sammensetninger som inneholder de samme
CY1125077T1 (el) Αγωγη της ανεπαρκειας και ελλειψης βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3
BRPI0618552B8 (pt) compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos
BRPI0622054B8 (pt) composto e composição farmacêutica
NO20064584L (no) Tetrahydropyridoindolderivater
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
BR112012024442A2 (pt) métodos de tratamento de câncer
MX2009009537A (es) Nanoparticula que comprende rapamicina y albumina como agente anticancer.
CL2008001839A1 (es) Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
WO2008082602A3 (en) Compounds and pharmaceutical compositions for the treatment of liver disorders
BR112021022897A2 (pt) Inibidor contendo derivado bicíclico, método de preparação do mesmo e uso do mesmo
NO20064054L (no) Terapeutiske kombinasjoner av atypiske antipsykotika med corticotropine frigivningsfaktor antagonister
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
NZ588913A (en) Liver cancer drug
WO2012027065A3 (en) Combination therapy for treatment of disease
EP2056818A4 (en) COMPOSITIONS AND METHODS FOR NEUROPROTECTION
CY1107906T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
NO20090887L (no) Fremgangsmate for behandling og forebygging av mukositt
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
WO2007097989A3 (en) A composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
WO2012096718A3 (en) Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers, and liver health maintenance
WO2008116161A3 (en) Pyrazoloanthrone and derivatives thereof for the treatment of cancer expressing 'mullerian inhibiting substance' type ii receptor (misrii) and of excess androgen states
NO20063987L (no) Anti-cancerterapier

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application